Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Chemotherapy + Quad Shot Radiotherapy in First-line Advanced NSCLC
NCT07271602Phase 2Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of QL1706 in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Objective Response Rate at 1 year. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07271602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07271602.